Physician profile
Sing W Law
NPI 1558324574
$1,324.05
in general payments reported to CMS, 2019-2025
12 companies · $43.13 in 2025
The $43.13 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $796 · 2020: $158 · 2021: $13.57 · 2023: $176 · 2024: $138 · 2025: $43.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $357.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $415.81 | 2019-2023 | Tezspire |
| Glaxosmithkline, LLC. | $288.92 | 2019-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $204.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $193.45 | 2019 | |
| Genzyme Corporation | $61.82 | 2024 | |
| Amgen INC. | $47.93 | 2019-2023 | Repatha, Otezla |
| Pfizer INC. | $26.94 | 2019 | |
| Electromed, INC. | $20.49 | 2019 | |
| Merck Sharp & Dohme LLC | $19.00 | 2020 | |
| Mylan Specialty L.P. | $17.50 | 2023 | Yupelri |
| Genentech USA, INC. | $15.00 | 2024 | Xolair |
| Lilly USA, LLC | $12.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sing Law listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.